Back
50
17
Also listed as
SNPHY
OTC
Day Range
$10.99
$10.99
52-Week Range
$8.88
$11.45
Volume
2,000
50D / 200D Avg
$9.69
/
$10.54
Prev Close
$10.99
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 0.1 | 0.4 |
| P/B | 0.0 | 2.9 |
| ROE % | 12.2 | 3.8 |
| Net Margin % | 12.1 | 3.9 |
| Rev Growth 5Y % | 4.7 | 10.0 |
| D/E | 0.1 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$177.59
$161.40 – $185.56
|
390 B | 1 |
| FY2029 |
$166.99
$151.77 – $174.49
|
370 B | 1 |
| FY2028 |
$134.13
$121.91 – $140.15
|
310 B | 1 |
Key Takeaways
Revenue grew 4.71% annually over 5 years — modest growth
Earnings grew 36.09% over the past year
ROE of 12.24% — decent returns on equity
Debt/Equity of 0.12 — conservative balance sheet
Generating 54.27B in free cash flow
P/E of 0.10 — trading at a low valuation
Growth
Revenue Growth (5Y)
4.71%
Revenue (1Y)-0.65%
Earnings (1Y)36.09%
FCF Growth (3Y)107.87%
Quality
Return on Equity
12.24%
ROIC10.97%
Net Margin12.09%
Op. Margin15.63%
Safety
Debt / Equity
0.12
Current Ratio2.58
Interest Coverage17.26
Valuation
P/E Ratio
0.10
P/B Ratio0.01
EV/EBITDA-1.18
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -0.65% | Revenue Growth (3Y) | 3.69% |
| Earnings Growth (1Y) | 36.09% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 4.71% | Earnings Growth (5Y) | 51.79% |
| Profitability | |||
| Revenue (TTM) | 300.00B | Net Income (TTM) | 36.26B |
| ROE | 12.24% | ROA | 8.86% |
| Gross Margin | 57.01% | Operating Margin | 15.63% |
| Net Margin | 12.09% | Free Cash Flow (TTM) | 54.27B |
| ROIC | 10.97% | FCF Growth (3Y) | 107.87% |
| Safety | |||
| Debt / Equity | 0.12 | Current Ratio | 2.58 |
| Interest Coverage | 17.26 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 0.10 | P/B Ratio | 0.01 |
| P/S Ratio | 0.01 | PEG Ratio | 0.35 |
| EV/EBITDA | -1.18 | Dividend Yield | 0.02% |
| Market Cap | 3.54B | Enterprise Value | -55.23B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 300.00B | 301.97B | 279.04B | 266.26B | 249.61B |
| Net Income | 36.26B | 26.64B | -14.95B | 27.22B | 6.83B |
| EPS (Diluted) | 103.68 | 72.37 | -38.58 | 67.97 | 17.06 |
| Gross Profit | 171.03B | 178.71B | 166.09B | 156.59B | 151.38B |
| Operating Income | 46.88B | 38.54B | -3.09B | 35.89B | 37.80B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 409.28B | 435.70B | 421.18B | 459.98B | 402.35B |
| Total Liabilities | 124.10B | 130.33B | 127.88B | 123.13B | 95.30B |
| Shareholders' Equity | 286.24B | 306.06B | 293.98B | 337.49B | 307.59B |
| Total Debt | 34.23B | 35.16B | 36.21B | 32.93B | 10.15B |
| Cash & Equivalents | 93.00B | 94.58B | 57.90B | 83.01B | 62.89B |
| Current Assets | 224.30B | 236.14B | 213.33B | 229.43B | 206.23B |
| Current Liabilities | 86.84B | 92.80B | 89.50B | 95.82B | 78.55B |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#293 of 820
#506 of 708
Recent Activity
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026